Radiotherapy reimagined: Integrating nanomedicines into radiotherapy clinical trials.

IF 6.9 2区医学 Q1 MEDICINE, RESEARCH & EXPERIMENTAL

Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology Pub Date : 2023-05-01 DOI:10.1002/wnan.1867

Allison N DuRoss, Jack Phan, Alexander J Lazar, Joshua M Walker, Alexander R Guimaraes, Carole Baas, Sunil Krishnan, Charles R Thomas, Conroy Sun, Alexander F Bagley

{"title":"Radiotherapy reimagined: Integrating nanomedicines into radiotherapy clinical trials.","authors":"Allison N DuRoss, Jack Phan, Alexander J Lazar, Joshua M Walker, Alexander R Guimaraes, Carole Baas, Sunil Krishnan, Charles R Thomas, Conroy Sun, Alexander F Bagley","doi":"10.1002/wnan.1867","DOIUrl":null,"url":null,"abstract":"<p><p>Radioenhancing nanoparticles (NPs) are being evaluated in ongoing clinical trials for various cancers including head and neck, lung, esophagus, pancreas, prostate, and soft tissue sarcoma. Supported by decades of preclinical investigation and recent randomized trial data establishing clinical activity, these agents are poised to influence future multimodality treatment paradigms involving radiotherapy. Although the physical interactions between NPs and ionizing radiation are well characterized, less is known about how these agents modify the tumor microenvironment, particularly regarding tumor immunogenicity. In this review, we describe the key multidisciplinary considerations related to radiation, surgery, immunology, and pathology for designing radioenhancing NP clinical trials. This article is categorized under: Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease.</p>","PeriodicalId":23697,"journal":{"name":"Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology","volume":"15 3","pages":"e1867"},"PeriodicalIF":6.9000,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"4","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/wnan.1867","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 4

Abstract

Radioenhancing nanoparticles (NPs) are being evaluated in ongoing clinical trials for various cancers including head and neck, lung, esophagus, pancreas, prostate, and soft tissue sarcoma. Supported by decades of preclinical investigation and recent randomized trial data establishing clinical activity, these agents are poised to influence future multimodality treatment paradigms involving radiotherapy. Although the physical interactions between NPs and ionizing radiation are well characterized, less is known about how these agents modify the tumor microenvironment, particularly regarding tumor immunogenicity. In this review, we describe the key multidisciplinary considerations related to radiation, surgery, immunology, and pathology for designing radioenhancing NP clinical trials. This article is categorized under: Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease.

查看原文本刊更多论文

重新构想放射治疗:将纳米药物纳入放射治疗临床试验。

放射增强纳米粒子(NPs)正在临床试验中进行评估，用于治疗各种癌症，包括头颈部、肺部、食道、胰腺、前列腺和软组织肉瘤。在数十年的临床前研究和最近建立临床活性的随机试验数据的支持下，这些药物有望影响包括放射治疗在内的未来多模式治疗模式。虽然NPs和电离辐射之间的物理相互作用已被很好地表征，但对这些药物如何改变肿瘤微环境，特别是肿瘤免疫原性知之甚少。在这篇综述中，我们描述了设计放射增强NP临床试验时与放射、外科、免疫学和病理学相关的关键多学科考虑因素。本文分类如下:治疗方法和药物发现>肿瘤疾病的纳米医学。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology NANOSCIENCE & NANOTECHNOLOGY-MEDICINE, RESEARCH & EXPERIMENTAL

CiteScore

16.60

自引率

2.30%

发文量

期刊介绍： Nanotechnology stands as one of the pivotal scientific domains of the twenty-first century, recognized universally for its transformative potential. Within the biomedical realm, nanotechnology finds crucial applications in nanobiotechnology and nanomedicine, highlighted as one of seven emerging research areas under the NIH Roadmap for Medical Research. The advancement of this field hinges upon collaborative efforts across diverse disciplines, including clinicians, biomedical engineers, materials scientists, applied physicists, and toxicologists. Recognizing the imperative for a high-caliber interdisciplinary review platform, WIREs Nanomedicine and Nanobiotechnology emerges to fulfill this critical need. Our topical coverage spans a wide spectrum, encompassing areas such as toxicology and regulatory issues, implantable materials and surgical technologies, diagnostic tools, nanotechnology approaches to biology, therapeutic approaches and drug discovery, and biology-inspired nanomaterials. Join us in exploring the frontiers of nanotechnology and its profound impact on biomedical research and healthcare.